Shopping Cart
- Remove All
- Your shopping cart is currently empty
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor, inhibiting IL-31 and OSM signaling. It can be used to study severe nodular itch and idiopathic pulmonary fibrosis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $372 | In Stock | |
5 mg | $997 | In Stock | |
10 mg | $1,590 | In Stock |
Description | Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor, inhibiting IL-31 and OSM signaling. It can be used to study severe nodular itch and idiopathic pulmonary fibrosis. |
In vitro | At a concentration of 0.0001 μg/mL, Vixarelimab (KPL-716) induces an increase in MCP-1/CCL2 levels in human epidermal keratinocytes (HEK) and human dermal fibroblasts (HDF). However, at concentrations of 0.001 μg/mL or higher, there is a significant decrease in MCP-1/CCL2 levels in both cell types[1]. Pre-treatment with Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) reduces MCP-1/CCL2 levels in both HEK and HDF cells induced by Oncostatin M (OSM) and OSM + IL-4. The maximum effect is observed at concentrations of 0.01 μg/mL and 0.1 μg/mL[1]. |
Alias | RO-7622888, RG-6536, KPL-716 |
Molecular Weight | 144.99 kDa |
Cas No. | 2243320-83-2 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.